The diversity increased greatly from benign to high-grade endometrial carcinoma and the benign condition, low-grade endometrial carcinoma and high-grade clustered into CST1, CST 2, and both CST3 and CST4, respectively (Hakimjavadi et al., 2022). This evidence concerns the gene CST1 and endometrial carcinoma.